公开(公告)号：US20230382850A1

公开(公告)日：2023-11-30

申请号：US18323277

申请日：2023-05-24

Applicant: Texas Tech University System

Inventor： Nadezhda German ,  Ruwein Zhang ,  Wei Wang ,  Constantinos Mikelis ,  Luca Cucullo

IPC: C07C275/30 ,  A61K45/06

CPC classification number: C07C275/30 ,  A61K45/06

Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat triple negative breast cancers (TNBCs). The class of urea compounds acts by blocking at inhibiting the mTOR signaling pathway, which, as a central regulator of mammalian metabolism and physiology that when inhibited leads to the induction of autophagocytosis. The disclosed compounds are further capable of reinitiating the p53 cycle as well as inhibition of the BNIP3/BNIP3L pathway. The disclosed compounds also shows the ability to cross the blood-brain-barrier where metastases can form. This new drug has the potential to be a powerful new treatment to combat invasive TNBCs.

公开(公告)号：US10472355B2

公开(公告)日：2019-11-12

申请号：US15513882

申请日：2015-09-25

Applicant: Texas Tech University System

Inventor： Ruiwen Zhang ,  Wei Wang

IPC: C07D471/04

Abstract: An SP-141 compound is a novel small molecule that can serve as a molecular-targeted chemotherapeutic agent. In one embodiment, the labeled compound can comprise SP-141, which comprises 6-methoxy-1-(naphthalen-1-yl)-9 H-pyrido[3,4-b]indote. The compound inhibits expression of oncogenes such as the Mouse Double Minute 2 protein. The compound can bind directly to Mouse Double Minute 2 to inhibit cancer growth including breast cancer growth.

公开(公告)号：US20210309607A1

公开(公告)日：2021-10-07

申请号：US17267439

申请日：2019-08-09

Applicant: Texas Tech University System

Inventor： Nadezhda German ,  Ruwein Zhang ,  Wei Wang ,  Constantinos Mikelis ,  Luca Cucullo

IPC: C07C275/30 ,  A61K45/06

Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat triple negative breast cancers (TNBCs). The class of urea compounds acts by blocking at inhibiting the mTOR signaling pathway, which, as a central regulator of mammalian metabolism and physiology that when inhibited leads to the induction of autophagocytosis. The disclosed compounds are further capable of reinitiating the p53 cycle as well as inhibition of the BNIP3/BNIP3L pathway. The disclosed compounds also shows the ability to cross the blood-brain-barrier where metastases can form. This new drug has the potential to be a powerful new treatment to combat invasive TNBCs.

公开(公告)号：US20170283413A1

公开(公告)日：2017-10-05

申请号：US15513882

申请日：2015-09-25

Applicant: Texas Tech University System

Inventor： Ruiwen Zhang ,  Wei Wang

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: An SP-141 compound is a novel small molecule that can serve as a molecular-targeted chemotherapeutic agent. In one embodiment, the labeled compound can comprise SP-141, which comprises 6-methoxy-1-(naphthalen-1-yl)-9 H-pyrido[3,4-b]indote. The compound inhibits expression of oncogenes such as the Mouse Double Minute 2 protein. The compound can bind directly to Mouse Double Minute 2 to inhibit cancer growth including breast cancer growth.